Page 1 | Search Results | Blood Advances | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Isabelle A. van Zeventer, Jonas B. Salzbrunn, Aniek O. de Graaf, Bert A. van der Reijden, H. Marike Boezen, Judith M. Vonk, Pim van der Harst, Jan Jacob Schuringa, Joop H. Jansen, Gerwin Huls

Blood Adv (2021) 5 (8): 2115–2122.

https://doi.org/10.1182/bloodadvances.2020004062

Published: 2021

Includes: Supplemental data

Journal Articles

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

Anthony M. Hunter, Rami S. Komrokji, Seongseok Yun, Najla Al Ali, Onyee Chan, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra L. Sweet, Jeffrey E. Lancet, Eric Padron, Alan F. List, David A. Sallman

Blood Adv (2021) 5 (4): 1017–1028.

https://doi.org/10.1182/bloodadvances.2020003508

Published: 2021

Includes: Supplemental data

Journal Articles

High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers

Hélène Guermouche, Noémie Ravalet, Nathalie Gallay, Caroline Deswarte, Amelie Foucault, Jenny Beaud, Emmanuelle Rault, Emeline Saindoy, Sébastien Lachot, Jean-Alain Martignoles, Valérie Gissot, Ludovic Suner, Emmanuel Gyan, François Delhommeau, Olivier Herault, Pierre Hirsch

Blood Adv (2020) 4 (15): 3550–3557.

https://doi.org/10.1182/bloodadvances.2020001582

Published: 2020

Includes: Supplemental data

Journal Articles

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms

Natasha E. Lewis, Kseniya Petrova-Drus, Sarah Huet, Zachary D. Epstein-Peterson, Qi Gao, Allison E. Sigler, Jeeyeon Baik, Neval Ozkaya, Alison J. Moskowitz, Anita Kumar, Steven M. Horwitz, Yanming Zhang, Maria E. Arcila, Ross L. Levine, Mikhail Roshal, Ahmet Dogan, Wenbin Xiao

Blood Adv (2020) 4 (10): 2261–2271.

https://doi.org/10.1182/bloodadvances.2020001636

Published: 2020

Includes: Supplemental data

Journal Articles

Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status

Blood Adv (2020) 4 (5): 845–854.

https://doi.org/10.1182/bloodadvances.2019001324

Published: 2020

Includes: Supplemental data

Journal Articles

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome

Emily F. Mason, Robert P. Hasserjian, Nidhi Aggarwal, Adam C. Seegmiller, Olga Pozdnyakova

Blood Adv (2019) 3 (21): 3322–3332.

https://doi.org/10.1182/bloodadvances.2019000328

Published: 2019

Includes: Supplemental data

Journal Articles

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

Gerbrig Berger, Mylene Gerritsen, Guoqiang Yi, Theresia N. Koorenhof-Scheele, Leonie I. Kroeze, Marian Stevens-Kroef, Kenichi Yoshida, Yuichi Shiraishi, Eva van den Berg, Hein Schepers, Geert Huls, André B. Mulder, Seishi Ogawa, Joost H. A. Martens, Joop H. Jansen, Edo Vellenga

Blood Adv (2019) 3 (20): 3111–3122.

https://doi.org/10.1182/bloodadvances.2019000518

Published: 2019

Includes: Supplemental data

Journal Articles

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

Mai Aly, Zubaidah M. Ramdzan, Yasunobu Nagata, Suresh K. Balasubramanian, Naoko Hosono, Hideki Makishima, Valeria Visconte, Teodora Kuzmanovic, Vera Adema, Aziz Nazha, Bartlomiej P. Przychodzen, Cassandra M. Kerr, Mikkael A. Sekeres, Mohamed E. Abazeed, Alain Nepveu, Jaroslaw P. Maciejewski

Blood Adv (2019) 3 (14): 2164–2178.

https://doi.org/10.1182/bloodadvances.2018028423

Published: 2019

Includes: Supplemental data

Journal Articles

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Blood Adv (2019) 3 (12): 1837–1847.

https://doi.org/10.1182/bloodadvances.2018028316

Published: 2019

Includes: Supplemental data

Journal Articles

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia

Blood Adv (2019) 3 (3): 339–349.

https://doi.org/10.1182/bloodadvances.2018024216

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical consequences of clonal hematopoiesis of indeterminate potential

David P. Steensma

Blood Adv (2018) 2 (22): 3404–3410.

https://doi.org/10.1182/bloodadvances.2018020222

Published: 2018

Journal Articles

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

Blood Adv (2018) 2 (20): 2658–2671.

https://doi.org/10.1182/bloodadvances.2018021469

Published: 2018

Includes: Supplemental data

Journal Articles

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes

Kazuaki Yokoyama, Eigo Shimizu, Nozomi Yokoyama, Sousuke Nakamura, Rika Kasajima, Miho Ogawa, Tomomi Takei, Mika Ito, Asako Kobayashi, Rui Yamaguchi, Seiya Imoto, Satoru Miyano, Arinobu Tojo

Blood Adv (2018) 2 (19): 2513–2521.

https://doi.org/10.1182/bloodadvances.2017010744

Published: 2018

Includes: Supplemental data

Journal Articles

Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells

Xi Jin, Tingting Qin, Meiling Zhao, Nathanael Bailey, Lu Liu, Kevin Yang, Victor Ng, Tomoyasu Higashimoto, Rosemary Coolon, Gina Ney, Maria E. Figueroa, Qing Li

Blood Adv (2018) 2 (11): 1259–1271.

https://doi.org/10.1182/bloodadvances.2018017400

Published: 2018

Includes: Supplemental data

Journal Articles

B-cell tumor development in Tet2 -deficient mice

Enguerran Mouly, Hussein Ghamlouch, Veronique Della-Valle, Laurianne Scourzic, Cyril Quivoron, Damien Roos-Weil, Patrycja Pawlikowska, Véronique Saada, M’Boyba K. Diop, Cécile K. Lopez, Michaela Fontenay, Philippe Dessen, Ivo P. Touw, Thomas Mercher, Said Aoufouchi, Olivier A. Bernard

Blood Adv (2018) 2 (6): 703–714.

https://doi.org/10.1182/bloodadvances.2017014118

Published: 2018

Includes: Supplemental data

Journal Articles

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber, Kebede H. Begna, Mrinal M. Patnaik, Naseema Gangat, Animesh Pardanani, Ayalew Tefferi

Blood Adv (2018) 2 (4): 370–380.

https://doi.org/10.1182/bloodadvances.2018015875

Published: 2018

Includes: Supplemental data

Journal Articles

RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells

Takahiro Suzuki, Yuri Shimizu, Erina Furuhata, Shiori Maeda, Mami Kishima, Hajime Nishimura, Saaya Enomoto, Yoshihide Hayashizaki, Harukazu Suzuki

Blood Adv (2017) 1 (20): 1699–1711.

https://doi.org/10.1182/bloodadvances.2017005710

Published: 2017

Includes: Supplemental data

Journal Articles

Targeted deep sequencing in primary myelofibrosis

Ayalew Tefferi, Terra L. Lasho, Christy M. Finke, Yoseph Elala, Curtis A. Hanson, Rhett P. Ketterling, Naseema Gangat, Animesh Pardanani

Blood Adv (2016) 1 (2): 105–111.

https://doi.org/10.1182/bloodadvances.2016000208

Published: 2016

Includes: Supplemental data

NARROW

Prevalence, predictors, and outcomes of clonal hematopoiesis in individuals aged ≥80 years

Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes

High prevalence of clonal hematopoiesis in the blood and bone marrow of healthy volunteers

Clonal hematopoiesis in angioimmunoblastic T-cell lymphoma with divergent evolution to myeloid neoplasms

Molecular pathogenesis of progression to myeloid leukemia from TET-insufficient status

Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome

Ring sideroblasts in AML are associated with adverse risk characteristics and have a distinct gene expression pattern

Distinct clinical and biological implications of CUX1 in myeloid neoplasms

A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients

Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia

Clinical consequences of clonal hematopoiesis of indeterminate potential

The mutational landscape of accelerated- and blast-phase myeloproliferative neoplasms impacts patient outcomes

Cell-lineage level–targeted sequencing to identify acute myeloid leukemia with myelodysplasia-related changes

Oncogenic N-Ras and Tet2 haploinsufficiency collaborate to dysregulate hematopoietic stem and progenitor cells

B-cell tumor development in Tet2 -deficient mice

Targeted next-generation sequencing in blast phase myeloproliferative neoplasms

RUNX1 regulates site specificity of DNA demethylation by recruitment of DNA demethylation machineries in hematopoietic cells

Targeted deep sequencing in primary myelofibrosis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only